UPCOMING SESSIONS in ET
Thu, May 21, 2026
5:00 – 6:00 AM Bangkok
Dr. Stacey Goodman: If I Knew Then What I Know Now: Lessons learned along my journey treating patients with Amyloidosis and in life Dr. Stacey Goodman Click To Register
UPCOMING SESSIONS in ET
Thu, May 21, 2026 · 5:00 – 6:00 AM Bangkok
Dr. Stacey Goodman: If I Knew Then What I Know Now: Lessons learned along my journey treating patients with Amyloidosis and in life
Dr. Stacey Goodman
Click To Register
View all sessions

Cardiac amyloidosis – when should I suspect it and what should I do?

Published: May 20, 2026
Key Information
Source
MedicineToday
summary/abstract
Abstract

Transthyretin-related cardiac amyloidosis is a progressive disease with significant morbidity and mortality if left untreated. With both hereditary and wild-type forms, and an often insidious presentation of symptoms, the diagnosis may easily be missed. Early specialist referral is essential if red flags are present.

Key Points
  • Transthyretin-related cardiac amyloidosis (ATTR-CA) is a frequently under-recognised cause of heart failure, particularly in older men.
  • There are two forms of ATTR-CA: wild-type ATTR, which typically affects older people, and hereditary or variant ATTR, which is caused by a genetic mutation.
  • Amyloid deposits often cause noncardiac problems years before cardiac symptoms appear. Key red flags include bilateral carpal tunnel syndrome, lumbar spinal stenosis and biceps tendon rupture.